Cerebral arteries

Spryte Medical Announces First Human Use of Novel Intravascular Brain Imaging Technology, Published in Science Translational Medicine

Retrieved on: 
星期三, 五月 15, 2024
Research, Technology, Medical Devices, Neurology, Health Technology, Radiology, General Health, Health, Science, Artificial Intelligence, Blood, Patient, Cerebrovascular disease, University of Massachusetts, X-ray, AAAS, OCT, University, Stroke, Science Translational Medicine, MD, AI, Anatomy, Cerebral arteries, Pathology, University of Toronto, Workflow, Medicine, Professor, Hospital, Brain, Physician, Angiography, Multimedia, Noct, Medical imaging

The device is not approved for human use in the USA or commercially available.

Key Points: 
  • The device is not approved for human use in the USA or commercially available.
  • “The Spryte nOCT technology is an imaging probe, sized like a guidewire, that navigates seamlessly through the brain vessels using our usual neuro-interventional techniques.
  • Science Translational Medicine is a perfect journal to showcase this work, bringing together scientific innovation and medical application.
  • “This study provides proof of concept for using optical coherence tomography devices to better understand cerebrovascular pathology and intervention for a range of conditions in the human brain,” said editor Brandon Berry from Science Translational Medicine.

Protembis Announces First Patient Enrolled in the PROTEMBO IDE Pivotal Trial

Retrieved on: 
星期二, 四月 2, 2024
General Health, Professional Services, Venture Capital, Medical Devices, Hospitals, Small Business, Clinical Trials, Surgery, Cardiology, Biotechnology, Finance, Health, Brain, Boston Scientific, Aortic stenosis, Cerebral arteries, NewYork-Presbyterian Hospital, Patient, Pivotal trial, IDE, Trial of the century, Hospital, DW, TAVR, Study, CEP, Medical imaging

Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816).

Key Points: 
  • Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816).
  • The trial will enroll between 250-500 randomized patients undergoing transcatheter aortic valve replacement (TAVR) in the USA and Europe with the ProtEmbo® System, an innovative next generation cerebral embolic protection device (CEP) providing complete 3-vessel coverage of the cerebral arteries.
  • The primary safety endpoint is the rate of major adverse cardiac and cerebrovascular events (MACCE) assessed at 30-days.
  • This significant progress reflects the close collaboration between our study executive committee, our clinical research organization, and core lab partners in planning this complex trial,” said Karl von Mangoldt and Conrad Rasmus Co-CEOs of Protembis.

Protembis Announces FDA Approval of its Pivotal Investigational Device Exemption (IDE) Study

Retrieved on: 
星期四, 十月 19, 2023
General Health, Professional Services, Venture Capital, Medical Devices, Hospitals, Small Business, Clinical Trials, Cardiology, Biotechnology, Finance, FDA, Health, Sentinel, Stroke, NewYork-Presbyterian Hospital, US, Neurology, Congress, Cerebral arteries, IDE, CEP, European, TAVR, Brain, DW, Patient, Boston Scientific, Hospital, Study, Pharmaceutical industry, Medical device

Protembis GmbH (Protembis) a privately-held emerging cardiovascular medical device company, announced today the FDA has approved the PROTEMBO Pivotal IDE Trial (NCT05873816).

Key Points: 
  • Protembis GmbH (Protembis) a privately-held emerging cardiovascular medical device company, announced today the FDA has approved the PROTEMBO Pivotal IDE Trial (NCT05873816).
  • The primary safety endpoint is the rate of major adverse cardiac and cerebrovascular events (MACCE) assessed at 30-days, with stroke neurologists adjudicating the neurological events.
  • “We are delighted to announce that the pivotal IDE trial has been approved by the US FDA.
  • The Protembis team is working hard with our investigational sites, which are high volume TAVR centers and world-renowned academic centers of excellence, to ensure study activation is achieved expeditiously.

Methinks receives CE Marked Certification for AI-based stroke triage software

Retrieved on: 
星期二, 二月 21, 2023
AIS, LVO, Reperfusion, CE, Physician, Hospital, Stroke, Systematic review, Diagnosis, PMID, CT, CTA, Literature, National library, Acquisition, Algorithm, Patient, Intracerebral hemorrhage, US FDA, Software, Artificial intelligence, Cooper University Hospital, The lady doth protest too much, methinks, Ambient occlusion, Death, FDA, Rehabilitation, Cerebral arteries, Total permanent disability insurance, ICH, Computed tomography angiography, Innovation system, NCCT, Medicine, Medical imaging, Medical device, Pharmaceutical industry

BARCELONA, Spain, Feb. 21, 2023 /PRNewswire/ -- Methinks, a digital health Company that specializes in early detection and management of Acute Stroke (AS), using artificial intelligence (AI), today announced that it has received CE mark for its medical imaging software, Methinks Stroke Suite following a milestone year of development progress, enabling commercialization in Europe and to assist in emergency settings for the benefit of AS patients.

Key Points: 
  • Methinks Stroke Suite is the first CE marked medical device that assists in finding large vessel occlusions (LVO) both hyperdense and not.
  • Acute stroke is a serious life-threatening medical condition that affects approximately 17 million people globally each year.
  • Methinks Stroke Suite, AI-based software, is a radiological computer aided triage and notification system which uses AI algorithms to identify suspected LVO on non-contrast computed tomography (NCCT) images and computed tomography angiography (CTA).
  • Pau Rodriguez, CEO of Methinks, said: "We are delighted with the CE mark approval for our medical imaging software, Methinks Stroke Suite, which paves the way to enhance stroke patient outcomes by decreasing detection time and reducing disabilities.

Methinks receives CE Marked Certification for AI-based stroke triage software

Retrieved on: 
星期二, 二月 21, 2023
AIS, LVO, Reperfusion, CE, Physician, Hospital, Stroke, Systematic review, Diagnosis, PMID, CT, CTA, Literature, National library, Acquisition, Algorithm, Patient, Intracerebral hemorrhage, US FDA, Software, Artificial intelligence, Cooper University Hospital, The lady doth protest too much, methinks, Ambient occlusion, Death, FDA, Rehabilitation, Cerebral arteries, Total permanent disability insurance, ICH, Computed tomography angiography, Innovation system, NCCT, Medicine, Medical imaging, Medical device, Pharmaceutical industry

BARCELONA, Spain, Feb. 21, 2023 /PRNewswire/ -- Methinks, a digital health Company that specializes in early detection and management of Acute Stroke (AS), using artificial intelligence (AI), today announced that it has received CE mark for its medical imaging software, Methinks Stroke Suite following a milestone year of development progress, enabling commercialization in Europe and to assist in emergency settings for the benefit of AS patients.

Key Points: 
  • Methinks Stroke Suite is the first CE marked medical device that assists in finding large vessel occlusions (LVO) both hyperdense and not.
  • Acute stroke is a serious life-threatening medical condition that affects approximately 17 million people globally each year.
  • Methinks Stroke Suite, AI-based software, is a radiological computer aided triage and notification system which uses AI algorithms to identify suspected LVO on non-contrast computed tomography (NCCT) images and computed tomography angiography (CTA).
  • Pau Rodriguez, CEO of Methinks, said: "We are delighted with the CE mark approval for our medical imaging software, Methinks Stroke Suite, which paves the way to enhance stroke patient outcomes by decreasing detection time and reducing disabilities.

Mentice AB intends to acquire all assets related to the software solution Ankyras from the Spanish corporation Galgo Medical S.L.

Retrieved on: 
星期四, 六月 9, 2022
Osteoporosis, Precision medicine, Company, Stroke, SEK, Medical device regulation, Aneurysm, Cerebral arteries, Cardiac electrophysiology, CEO, Information, New York City Department of Information Technology and Telecommunications, Solution, Brain, Hospital, Technology, Acquisition, Department, EUR, Intention, Disclosure, Pompeu Fabra University, Galgo, Death, Medical imaging, Pharmaceutical industry, EU

The Acquisition is characterized as a technology acquisition as this solution is in an early phase of its commercialization.

Key Points: 
  • The Acquisition is characterized as a technology acquisition as this solution is in an early phase of its commercialization.
  • However, the solution has been developed for a long time by Galgo and the software Ankyras is patent protected and CE-marked product (Medical Device Regulation MDR) with technology published by Galgo since 2013.
  • Ankyras is an advanced cloud-based analysis solution that allows a physician to plan treatment for a specific patient.
  • This disclosure contains information that Mentice AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014).

Mentice AB intends to acquire all assets related to the software solution Ankyras from the Spanish corporation Galgo Medical S.L.

Retrieved on: 
星期四, 六月 9, 2022
Osteoporosis, Precision medicine, Company, Stroke, SEK, Medical device regulation, Aneurysm, Cerebral arteries, Cardiac electrophysiology, CEO, Information, New York City Department of Information Technology and Telecommunications, Solution, Brain, Hospital, Technology, Acquisition, Department, EUR, Intention, Disclosure, Pompeu Fabra University, Galgo, Death, Medical imaging, Pharmaceutical industry, EU

The Acquisition is characterized as a technology acquisition as this solution is in an early phase of its commercialization.

Key Points: 
  • The Acquisition is characterized as a technology acquisition as this solution is in an early phase of its commercialization.
  • However, the solution has been developed for a long time by Galgo and the software Ankyras is patent protected and CE-marked product (Medical Device Regulation MDR) with technology published by Galgo since 2013.
  • Ankyras is an advanced cloud-based analysis solution that allows a physician to plan treatment for a specific patient.
  • This disclosure contains information that Mentice AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014).

Global Percutaneous Transluminal Angioplasty Balloons Catheter Market Report to 2028 - Size, Share, Outlook, and Opportunity Analysis - ResearchAndMarkets.com

Retrieved on: 
星期二, 四月 26, 2022
Health, Other Health, Neck, Groin, Marketing, Medtronic, Percutaneous, Angioplasty, Brain, CAGR, Region, PTA, Knee, Application, US, Cerebral arteries, Plaque, Wrist, Chameleon, Common carotid artery, Industry, Arm, Atherosclerosis, Medical imaging

The "Percutaneous Transluminal Angioplasty Balloons Catheter Market, by Type, by Material, by Application, by Diameter Size, by End User and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Percutaneous Transluminal Angioplasty Balloons Catheter Market, by Type, by Material, by Application, by Diameter Size, by End User and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • Percutaneous transluminal angioplasty (PTA) is a procedure that opens up blocked peripheral arteries due to plaque build-up (atherosclerosis).
  • A series of x-ray images are taken to clearly view the narrowed artery after the catheter is advanced into the narrowed artery.
  • Increasing launches of angioplasty balloons catheter products in the market by key players are expected to drive the global percutaneous transluminal angioplasty balloons catheter market growth during the forecast period.